AGS-1C4D4 is a fully human IgG1κ monoclonal antibody targeting PSCA, with a K d value of 0.2 nM. AGS-1C4D4 mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity ( CDC ) against PSCA-expressing cells. AGS-1C4D4 can be used for the research of pancreatic cancer [1].
In Vivo, AGS-1C4D4 significantly inhibits established pancreatic tumor growth and metastasis in orthotopic HPAC xenograft models when combined with Gemcitabine, and also significantly inhibits pancreatic tumor formation, local invasion, and distant metastasis in the same orthotopic xenograft model[1].
In Vitro, AGS-1C4D4 displays potent ADCC activity against PSCA-expressing HPAC and Panc0203 pancreatic cell lines, with activity greatly reduced by deglycosylation, and is more potent than the hybridoma-derived AGS-PSCA antibody in this assay[1]. AGS-1C4D4 exhibits CDC activity against PSCA-expressing recombinant B300.19 cells, with activity greatly reduced by deglycosylation, and is equally effective as the hybridoma-derived AGS-PSCA antibody in this assay[1]. AGS-1C4D4 binds to PSCA with a Kd of 0.2 nM, displaying similar binding affinity to the hybridoma-derived AGS-PSCA antibody[1].
References:
[1]. Tony Navas, et al. Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer. Cancer Res (2011) 71 (8_Supplement): 4566.
In Vivo, AGS-1C4D4 significantly inhibits established pancreatic tumor growth and metastasis in orthotopic HPAC xenograft models when combined with Gemcitabine, and also significantly inhibits pancreatic tumor formation, local invasion, and distant metastasis in the same orthotopic xenograft model[1].
In Vitro, AGS-1C4D4 displays potent ADCC activity against PSCA-expressing HPAC and Panc0203 pancreatic cell lines, with activity greatly reduced by deglycosylation, and is more potent than the hybridoma-derived AGS-PSCA antibody in this assay[1]. AGS-1C4D4 exhibits CDC activity against PSCA-expressing recombinant B300.19 cells, with activity greatly reduced by deglycosylation, and is equally effective as the hybridoma-derived AGS-PSCA antibody in this assay[1]. AGS-1C4D4 binds to PSCA with a Kd of 0.2 nM, displaying similar binding affinity to the hybridoma-derived AGS-PSCA antibody[1].
References:
[1]. Tony Navas, et al. Abstract 4566: AGS-1C4D4: A fully human anti-PSCA antibody inhibits tumor formation and metastasis in orthotopic models of pancreatic cancer. Cancer Res (2011) 71 (8_Supplement): 4566.